A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eRapid Nebulizer System in Patients With Cystic Fibrosis - Trial 2015-003537-99
Access comprehensive clinical trial information for 2015-003537-99 through Pure Global AI's free database. This phase not specified trial is sponsored by F. Hoffmann-La Roche AG and is currently status unknown. The study focuses on Cystic Fibrosis.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
2015-003537-99
Trial Details
EU Clinical Trials Register • 2015-003537-99
A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eRapid Nebulizer System in Patients With Cystic Fibrosis
Study Focus
Sponsor & Location
F. Hoffmann-La Roche AG
Timeline & Enrollment
N/A
N/A
N/A
Primary Outcome
- An acute respiratory infection or pulmonary exacerbation within 4 weeks prior to randomization
ICD-10 Classifications
Cystic fibrosis
Cystic fibrosis, unspecified
Cystic fibrosis with other manifestations
Cystic fibrosis with pulmonary manifestations
Cystic fibrosis with intestinal manifestations
Data Source
EU Clinical Trials Register
2015-003537-99
Non-Device Trial